




The relative strengths and weaknesses of Akari Therapeutics Plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akari Therapeutics Plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Akari Therapeutics Plc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 256%, being 7.1% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	69,658
Cost of Goods Sold	0
Intangible Assets	52
Liabilities, Current	21,125
Liabilities, Non-Current	49
Other Assets	142
Other Compr. Net Income	110
Other Expenses	19,283
Other Liabilities	0
Other Net Income	-14,733
Other Revenues	0
Property and Equipment	41
Research and Development	5,799
Selling, General and Administrative Expense	5,502

Output Variable	Value in 1000 USD
Assets	69,894
Liabilities	21,174
Expenses	30,585
Revenues	0
Stockholders Equity	48,720
Net Income	-45,318
Comprehensive Net Income	-45,262
BaseVar	68,248
ECR before LimitedLiability	134%
Economic Capital Ratio	256%